Ar­ray shares surge as sec­ond chap­ter of its PhI­II can­cer com­bo sto­ry ends on an up­beat note

Ar­ray Bio­phar­ma stock got a bounce out of the up­beat as­sess­ment of the sec­ond part of its Phase III study of binime­tinib com­bined with en­co­rafenib, demon­strat­ing their abil­i­ty to sig­nif­i­cant­ly im­prove pro­gres­sion free sur­vival rates for pa­tients with BRAF-mu­tant ad­vanced melanoma. The top-line re­sults lay the foun­da­tion for an NDA, the com­pa­ny adds, which is ex­pect­ed to be de­liv­ered to the FDA this sum­mer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.